Reuters logo
Pozen to submit response for migraine drug within 10 days
October 5, 2007 / 12:52 PM / 10 years ago

Pozen to submit response for migraine drug within 10 days

Oct 5 (Reuters) - U.S. drugmaker Pozen Inc POZN.O said within the next ten days it plans to respond to U.S. regulators, clarifying non-clinical information to further address concerns regarding the genotoxic potential of Trexima.

It will also submit a routine clinical safety update.

The move is in response to the approvable letter for migraine drug Trexima received on Aug. 1 from the U.S. Food and Drug Administration, the company said in a statement. (Reporting by Sreerupa Mitra in Bangalore)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below